Prepartum anaemia: prevention and treatment by Nils Milman
REVIEW ARTICLE
Prepartum anaemia: prevention and treatment
Nils Milman
Received: 24 April 2008 /Accepted: 26 May 2008 / Published online: 19 July 2008
# The Author(s) 2008
Abstract This review focuses on the occurrence, preven-
tion and treatment of anaemia during pregnancy in Western
societies. Iron deficiency anaemia (IDA) is the most
prevalent deficiency disorder and the most frequent form
of anaemia in pregnant women. Minor causes of anaemia
are folate and vitamin B12 deficiency, haemoglobinopathy
and haemolytic anaemia. Anaemia is defined as haemoglobin
of <110 g/L in the first and third trimester and <105 g/L in the
second trimester. The diagnosis relies on haemoglobin, a full
blood count and plasma ferritin, which can be supported by
plasma transferrin saturation and serum soluble transferrin
receptor. Among fertile, non-pregnant women, ∼40% have
ferritin of ≤30 μg/L, i.e. small or absent iron reserves and
therefore an unfavourable iron status with respect to upcoming
pregnancy. The prevalence of prepartum anaemia in the third
trimester ranges 14–52% in women taking placebo and 0–
25% in women taking iron supplements, dependent on the
doses of iron. In studies incorporating serum ferritin, the
frequency of IDA in placebo-treated women ranges 12–17%
and in iron-supplemented women 0–3%. Requirements for
absorbed iron increase during pregnancy from 0.8 mg/day in
the first trimester to 7.5 mg/day in the third trimester, on the
average ∼4.4 mg/day, and dietary measures are inadequate to
reduce the frequency of prepartum IDA. However, IDA is
efficiently prevented by oral iron supplements in doses of 30–
40 mg ferrous iron taken between meals from early pregnancy
to delivery. Treatment of IDA should aim at replenishing body
iron deficits by oral and/or intravenous administration of iron.
In women with slight to moderate IDA, i.e. haemoglobin of
90–105 g/L, treatment with oral ferrous iron of ∼100 mg/day
between meals is the therapeutic option in the first and second
trimester; haemoglobin should be checked after 2 weeks and
provided an increase of ≥10 g/L, oral iron therapy has proved
effective and should continue. Treatment with intravenous
iron is superior to oral iron with respect to the haematological
response. Intravenous iron is considered safe in the second
and third trimester, while there is little experience in the first
trimester. Intravenous iron of 600–1,200 mg should be
considered: (1) as second option if oral iron fails to increase
haemoglobin within 2 weeks; (2) as first option at profound
IDA, i.e. haemoglobin of <90 g/L in any trimester beyond 14
weeks gestation; and (3) as first option for IDA in third
trimester. Profound IDA has serious consequences for both
woman and foetus and requires prompt intervention with
intravenous iron. This is especially important for the safety of
women who for various reasons oppose blood transfusions.
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Introduction
Iron is an essential micronutrient to man. It is necessary for
the synthesis of the haemoglobin in erythrocytes and the
myoglobin in myocytes as well as for the function of a wide
range of iron-dependent enzymes. An adequate body iron
balance is important for our well-being and quality of life
[1–3]. In pregnant women, a favourable iron status is a
prerequisite for a good course of pregnancy, a normal
development of the foetus and maturity of the newborn.
There is evidence that iron deficiency, even in the absence
of iron deficiency anaemia (IDA), may have a negative
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impact in non-pregnant women, e.g. in relation to decreased
cognitive ability and physical performance [1, 2]. In
postpartum women, IDA is associated with emotional
instability, depression, stress and lower cognitive perfor-
mance tests [3]. It is therefore most likely that IDA has the
same effect on pregnant women. Furthermore, IDA during
pregnancy (prepartum) is associated with premature birth,
low birth weight and small for gestational age of the newborn
[4–8]. In addition, prepartum IDA predisposes to postpar-
tum IDA [9] and therefore deserves special attention.
We know that iron deficiency and IDA is the most
prevalent nutritional deficiency disorder in fertile women
on a global scale [10]. There are, however, major differ-
ences in iron nutrition between women from developing
and developed countries [10]. In developing regions of the
world, prepartum IDA is more the rule than the exception
with a prevalence of ∼52% [10], whereas in the affluent
Western societies the prevalence is far lower due to better
nutrition, ∼25% in women not taking iron supplements [10,
11] and <5% in women taking ≥40 mg ferrous iron daily
[11, 12]. This review shall focus on prevention and
treatment of prepartum anaemia in the Western societies.
Assessing iron status
Iron status can be assessed prepartum by using appropriate
markers, predominantly plasma ferritin, plasma transferrin
saturation, serum “soluble” transferrin receptor (sTfR) and
blood haemoglobin including a full blood count. In healthy
subjects, the plasma ferritin concentration is a biomarker for
mobilisable body iron reserves, i.e. iron status [13, 14]. In
non-pregnant women, a ferritin concentration of 1 μg/L
corresponds to 7–8 mg of mobilisable iron [13]. In general,
ferritin levels of <30 μg/L indicate a low iron status, i.e.
small or no iron reserves as verified by the absence of bone
marrow haemosiderin [14, 15]. Ferritin levels of <15 μg/L
is consistent with iron depletion and ferritin levels of
<12 μg/L are associated with IDA [15, 16]. In women with
inflammatory or infectious disorders, plasma ferritin can be
falsely elevated, i.e. out of proportion with body iron
reserves. If such conditions are suspected, plasma C-
reactive protein should be measured as well, in order to
assess the degree of inflammation.
Plasma transferrin saturation is calculated from measure-
ment of plasma iron and plasma transferrin. A saturation of
<15% is considered to indicate an inadequate supply of iron
to the erythrons and tissues [16].
The surface of young erythrocytes is crowded with
transferrin receptors, which increase in number during iron
deficiency [17]. Detached receptors can be measured in
serum as soluble receptors (sTfR). In the presence of iron
deficiency, serum sTfR rises [17]. Non-pregnant and
pregnant women with replete iron stores have similar serum
sTfR levels [18]. Serum sTfR can be used to identify
women with low plasma ferritin, who in addition have
pronounced iron deficiency [18, 19]. The physiologic
variations in ferritin may be compensated for by calculating
body iron using the sTfR-to-ferritin ratio [20, 21]. The
haemoglobin concentration is still widely used as a marker
for iron deficiency. However, haemoglobin is not suitable to
assess iron status—especially not in pregnancy where the
women display various degrees of haemodilution [22]. In
addition, there is a large overlap between the distribution of
haemoglobin concentrations in women with and without
iron deficiency as shown in Fig. 1 [23].
In short, plasma ferritin provides information about the
capacity of body iron reserves, serum sTfR and to some
extent plasma transferrin saturation yield information about
iron deficiency on the cellular level, whereas haemoglobin
gives information about iron deficiency on the functional
level. For practical purposes, haemoglobin, i.e. a full blood
count, and plasma ferritin are adequate to assess iron status
and diagnose IDA in the majority of women.
Iron requirements in pregnancy
The requirements for absorbed iron increase from 0.8 mg/day
in the first trimester to 7.5 mg/day in the third trimester.
The average requirement in the entire gestation period is ∼4.4
mg/day [9, 24].
The average total iron requirements in normal pregnancy
have been estimated to be ∼1,240 mg [9, 24]. Postpartum,
the mother’s erythrocyte mass declines to pre-pregnancy
levels, and the haemoglobin iron is recycled to body iron
reserves. The net iron loss, associated with pregnancy per
se, is therefore lower, approximately 630 mg [9, 24].
Fig. 1 Distribution of blood haemoglobin concentrations in non-
pregnant women with replete iron stores (serum ferritin>30 μg/L) and
absent iron stores (serum ferritin<12 μg/L) [23]
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Fertile women have a low iron status prior to pregnancy
Scandinavian studies have shown that the majority of
menstruating, non-pregnant women have a low iron status
with a median plasma ferritin of 38–40 μg/L; 10% of non-
blood-donors and 21% of blood donors have ferritin of <15
μg/L, i.e. iron depletion, and ∼4% have IDA. In total, 42%
have ferritin of ≤30 μg/L, i.e. small or absent iron reserves
[23, 25]. This means that ∼40% of women have an
unfavourable pre-pregnancy iron status.
Only 14–20% have ferritin of >70 μg/L, i.e. iron
reserves of ≥500 mg [23, 25], which almost balances the
net iron loss in pregnancy [9, 24]; these women have
adequate iron reserves and can carry through pregnancy
without developing IDA even though they do not take iron
supplements [26].
Certain subgroups of women within the European
societies have a higher risk for iron deficiency. These
include multipara, multiple pregnancies, blood donors,
vegetarians, women of low socio-economic status and
immigrants, especially from the Middle and Far East [27].
Defining prepartum anaemia
The majority of pregnant women in the Western societies
presenting with prepartum anaemia have IDA. In a small
fraction, other causes of anaemia prevail, mainly folate and/
or vitamin B12 deficiency and inflammatory or infectious
diseases. However, recent studies have shown that both
plasma folate and plasma cobalamin decrease markedly
during pregnancy [28, 29] suggesting that deficiency of
these vitamins may play a yet unidentified role. Women
from the Mediterranean, Middle and Far East and Africa
may have haemoglobinopathies, which can cause prepar-
tum anaemia. In addition, these women are more prone to
present with vitamin deficiencies. In Denmark, these
women are screened for haemoglobinopathy in the antenatal
health care system.
IDA is by definition an anaemia, which responds to
treatment with iron. There exist marked differences be-
tween haemoglobin levels in iron-supplemented and non-
supplemented pregnant women [11, 30]. It is hardly the
intention of nature that women shall be iron deficient while
being pregnant and we have therefore defined the haemo-
globin concentrations found in women without iron
deficiency as “optimum” normal values. The haemodilution
[22] induces physiological fluctuations in haemoglobin
during pregnancy [11, 31, 32]. In iron-supplemented
women, haemoglobin concentrations display a steady fall
from late first trimester due to haemodilution, reaching a
nadir at ∼25 weeks gestation. Subsequently, haemoglobin
rises during the remaining period of pregnancy to reach
peak levels shortly before delivery [11, 33–38]. This rise
prior to delivery is elicited by a combination of an increase
in the haemoglobin mass and a decrease in haemodilution.
The fluctuations in haemoglobin are different in placebo-
treated women, where levels continue to fall until ∼32
weeks gestation, probably due to iron-deficient erythropoi-
esis, and thereafter remain quite stable apart from a minor
increase shortly before delivery, probably caused by the
decrease in haemodilution [11, 33–38]. As the degree of
haemodilution displays considerable inter-individual varia-
tion, “normal” haemoglobin concentrations show similar
variation and makes it somewhat complicated to establish
reliable cutoff limits for anaemia.
Scandinavian studies [11, 31, 32] on healthy pregnant
Caucasian women without iron deficiency, and living at sea
level, have shown that the fifth percentile for blood
haemoglobin was 111 g/L in the first trimester and 109 g/L
in the first, 106 g/L in the second and 103 g/L in the last third
of the second trimester and 105 g/L in the first two thirds and
110 g/L in the last third of the third trimester. Virtually none
of the iron-replete women had values <100 g/L [11, 36, 38].
A Danish study [32] on iron-supplemented healthy preg-
nant women assessed “normal range” using the 95%
reference intervals and found reference values for haemo-
globin of 105, 103 and 108 g/L at 18, 32 and 39 weeks
gestation, respectively.
In order to make these values applicable in the clinical
situation, we have simplified the cutoff values for anaemia
to: haemoglobin<110 g/L (<6.8 mmol/L) in the first and
third trimester and <105 g/L (<6.5 mmol/L) in the second
trimester. This definition of prepartum anaemia is close to
the cutoff value of 110 g/L as proposed by the World
Health Organisation (WHO) during the entire gestation
period [10]. The relationship between haemoglobin (Hb) in
grammes per litre and millimoles per litre is expressed in
the following equations: Hb g/L × 0.062054=Hb mmol/L;
Hb mmol/L × 16.115=Hb g/L.
How frequent is prepartum anaemia?
There is a lack of systematic, epidemiological studies on the
frequency of prepartum anaemia. In Denmark, the National
Board of Health does not recommend routine check of
haemoglobin in pregnancy. However, at the discretion of their
general physician, many women have their haemoglobin
measured at their first antenatal visit at 12–14 weeks gestation
together with obligatory screening tests for hepatitis virus
infection, human immunodeficiency virus infection, etc.
During the remaining period of pregnancy, haemoglobin is
checked only if the medical history or the clinical examination
of the midwife at the antenatal care clinic suggests that the
woman may have anaemia.
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It is obvious that the frequency of prepartum IDA is
dependent on the woman’s iron status prior to pregnancy.
During pregnancy, dietary and supplemental iron intake,
iron bioavailability, impaired iron absorption due to
gastrointestinal diseases and unphysiological blood losses,
e.g. uterine haemorrhage, may all contribute to IDA.
The guidelines concerning iron prophylaxis towards IDA
during pregnancy vary from country to country (see below)
and the frequency of prepartum anaemia would therefore be
expected to show similar variations. Despite recommenda-
tions on iron prophylaxis, prepartum anaemia is still a
major antenatal problem. According to WHO [10], the
estimated number of women with prepartum anaemia in
Europe is ∼2.5 million.
In order to assess this issue, we have to look at
randomised, placebo-controlled studies on iron supplementa-
tion, which can give an impression of how frequent anaemia
and IDA occurs in pregnant women not taking iron supple-
ments [30]. All studies have reported mean haemoglobin
values during pregnancy, which consistently are significantly
lower in placebo-treated than in iron-supplemented women
[11, 33–41].
In a Danish placebo-controlled study of pregnant women
(107 on placebo, 100 on 66 mg elemental ferrous iron per
day, from ∼14 weeks gestation) having their haemoglobin
measured at regular intervals until delivery (Fig. 2), 5% of
placebo-treated vs 7% of iron-treated women had anaemia
in late second trimester, whereas 22% vs 2% had anaemia
in late third trimester [11].
Table 1 gives an overview of placebo-controlled iron
prophylaxis studies on pregnant women in the Western
societies, which have reported the occurrence of anaemia
[11, 34, 36–41]. All studies consistently show that women
taking placebo have a markedly higher frequency of
anaemia in the second and third trimester compared to
women taking iron supplements. In women taking placebo,
the frequency of anaemia in the third trimester ranges 14–
52% and in women taking iron supplements 0–25%,
dependent on the doses of iron. In studies incorporating
plasma ferritin, the frequency of IDA in placebo-treated
women ranges 12–17% and in iron-supplemented women
0–3% [11, 12, 38, 41].
Table 2 further illustrates that, in healthy Danish women,
the frequency of low haemoglobin levels is significantly
higher in placebo-treated than in iron-supplemented women.
From all these studies, we can conclude that in the Western
societies, prepartum anaemia is still a conspicuous problem
in the antenatal health care.
Evaluation of prepartum anaemia
When a pregnant woman is presenting in the antenatal
clinic with anaemia, it is essential to obtain a correct
diagnosis in order to institute a specific treatment. The first
important step for diagnosing anaemia include a thorough
medical history and a medical examination. In the majority
of women, i.e. ∼98%, the anaemia is caused by iron
deficiency, which can be confirmed by the examination of
appropriate biomarkers of iron status (plasma ferritin,
plasma transferrin saturation, serum sTfR). If these tests
are indicative of IDA, it should be considered whether the
degree of anaemia is consistent with the frequent IDA of
pregnancy occurring in women who do not take iron
supplements and/or have a low dietary iron intake with a
low bioavailability. If IDA occurs in women who take iron
supplements, “non-physiologic” causes, e.g. overt or occult
bleeding or impaired gastrointestinal iron absorption due to
gastric hypochlorhydria or achlorhydria or inflammatory
bowel disease, should be considered.
If IDA can be excluded, further evaluation for anaemia
should be performed dependent on the history and ethnicity,
e.g. plasma folate and plasma cobalamin status, examination
for haemolytic anaemia with appropriate tests, examination for
haemoglobinopathy with haemoglobin electrophoresis, etc.
Prevention of prepartum vitamin-deficiency-induced
anaemia
It is essential to maintain an optimum vitamin–mineral
status during pregnancy and avoid vitamin deficiencies in
Fig. 2 Blood haemoglobin concentrations (mean±SEM) during
pregnancy in women taking placebo vs. 66 mg ferrous iron per day
from 14 to 18 weeks gestation to delivery [11]
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order to provide the best nutritional conditions for the
pregnant women and for the foetus. With the intension to
secure adequate vitamin–mineral supplies, the Danish Na-
tional Board of Nutrition in 2005 (http://www.altomkost.dk,
March 2008) and the Danish Advisory Board of Nutrition in
2007 (http://www.meraadet.dk, March 2008) recommended
that pregnant women should take a multivitamin–mineral
tablet daily during pregnancy. Ideally, these tablets should be
taken in the period prior to conception in order to prevent
neural tube defects [42]. Multivitamin–mineral tablets
designed for pregnancy contain 0.4 mg folic acid, 1–2 μg
vitamin B12 and the various A, B, C, D and E vitamins.
Table 1 Frequency of prepartum anaemia in placebo-controlled studies of iron prophylaxis in Europe and Australia and a Danish dose–response
study








Fleming et al. 1974 [39] Placebo 45 60 20 weeks to term 20 weeks to delivery 20 (Hb<100 g/L)
Iron 57 7 (Hb<100 g/L)
Puolakka et al. 1980 [34] Placebo 16 200 16 weeks to term Delivery 31
Iron 16 0
Foulkes and Goldie 1982 [40] Placebo 250 100 12 weeks to term Delivery 19 (Hb<105 g/L)
Iron 251 5 (Hb <105 g/L)
















Milman et al. 1991 [11] Placebo 108 66 ∼14 weeks to term 14–18 weeks 2 12b
23–26 weeks 5
Delivery 14 0b
Iron 99 14–18 weeks 0
23–26 weeks 7
Delivery 0
Eskeland et al. 1997 [38] Placebo 23 27 20 weeks to term 20 weeks to delivery 52 17c
Iron 48 25 0c
Makrides et al. 2003 [41] Placebo 214 20 20 weeks to term 28 weeks 25 12b
Iron 216 10 3b
Milman et al. 2005 [12] Iron 105 20 18 weeks to term 18 weeks 2 9b
32 weeks 18
Delivery 3
Iron 322 40, 60, 80 18 weeks 1 1b
32 weeks 9
Delivery 3
Haemoglobin=Hb<105 g/L in second and <110 g/L in first and third trimester unless otherwise stated
SF Serum ferritin, IDA iron deficiency anaemia
a Hb<110 g/L
b SF<12 μg/L and Hb<110 g/L
c SF<15 μg/L and Hb<100 g/L
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Guidelines for prevention of prepartum iron deficiency
anaemia
European Union guidelines
The European Commission’s report from 1993 [43]
concludes that: “The physiologic solution for covering the
high iron requirements in pregnancy is to use iron from
stores. The problem, however, is that very few women, if
any, have iron stores of this magnitude. Therefore, daily
iron supplements are recommended in the latter half of
pregnancy”. To the author’s knowledge, these guidelines
have not been updated.
Country-specific guidelines
Some countries, e.g. Germany, have no official guidelines on
prepartum iron prophylaxis (http://www.frauenaerzte-im-
netz.de, March 2008; http://www.gesundheitpro.de, March
2008). Other countries have quite different guidelines.
Some advocate dietary measures, e.g., England and Wales
by the National Collaborating Centre for Women’s and
Children’s Health (http://www.rcog.org.uk/resources/Public/
pdf/Antenatal_Care.pdf, March 2008) and Norway by the
National Board of Social Welfare and Health (http://www.
shdir.no/publikasjoner, March 2008). Several countries ad-
vocate oral iron supplementation, e.g. USA by the Centres
for Disease Control and Prevention [44] and the International
Food Information Council Foundation (http://www.ific.org),
Denmark by the National Board of Health (http://www.
altomkost.dk, March 2008) and the Advisory Board of
Nutrition (http://www.meraadet.dk, March 2008) and Sweden
by the National Board of Nutrition (http://www.slv.se, March
2008).
The health authorities in the USA recommend general
iron prophylaxis with 30 mg ferrous iron per day at bedtime
from the first visit at the maternity clinic to delivery (http://
www.ific.org) [44]. In Denmark, the National Board of
Health and the National Board of Nutrition recommend
general iron prophylaxis of 50–70 mg of ferrous iron per
day at bedtime from 20 weeks gestation to delivery (http://
www.altomkost.dk, March 2008) whereas the Advisory
Board of Nutrition advocates individual iron prophylaxis
from early pregnancy to delivery using ferrous iron in doses
adjusted according to iron status (http://www.meraadet.dk,
March 2008).
Prophylaxis of prepartum iron deficiency anaemia
Dietary measures
In some countries (http://www.rcog.org.uk/resources/Public/
pdf/Antenatal_Care.pdf, March 2008; http://www.shdir.no/
publikasjoner, March 2008), guidelines to pregnant women
are focussed on changing dietary habits towards foods with
high iron content and high iron bioavailability. However,
this approach is purely theoretical and has not, to the
author’s knowledge, been substantiated by any controlled
study.
Overall, women do not change their dietary habits during
pregnancy [45], so we can estimate dietary intakes from
nutrition surveys in non-pregnant women. Danish menstru-
ating non-pregnant women have a mean dietary iron intake
of ∼9 mg/day [46], which means that more than 90% of the
women have an intake below the recommended daily
allowance of ∼18 mg/day [47].
A Scandinavian survey reported that the energy intake
and composition of the diet was similar prior to pregnancy
and at 17 and 33 weeks gestation [45]. Mean energy intake
was ∼9 mJ/day [45], i.e. the same as in non-pregnant
women [46]; 96% of the women had a dietary iron intake
below 18 mg/day. Thus, the majority of fertile women in
the Western countries have a dietary iron intake, which
cannot fulfil the demands in the second and third trimester.
The inadequate iron intake is predominantly caused by a
low energy intake, which is a consequence of the prevailing
sedentary lifestyle in the Western societies.
Table 2 Low haemoglobin and iron deficiency anaemia in women taking placebo or iron supplements during pregnancy [11]
Gestation (weeks) 14-18 19-22 23-26 27-30 31-34 35-38 39-43
Trimester 2 2 2 3 3 3 3
Placebo (n) 46 57 56 56 57 57 24
Low Hba (%) 20 14 5 16 19 30 42
IDAb (%) 0 0 0 5.4 10.5 17.5 20.8
Ferrous iron, 66 mg/day (n) 47 61 62 61 62 59 29
Low Hba (%) 9 5 2 3 5 9 10
IDAb (%) 0 0 0 0 0 0 0
Hb fifth percentile (g/L) in iron-replete women 110 106 103 106 106 110 114
a Haemoglobin (Hb) below fifth percentile in iron-replete women
b Iron deficiency anaemia: serum ferritin<12 μg/L and Hb below fifth percentile in iron-replete women
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Even under favourable conditions, at the most, 30% of
dietary iron can be absorbed, corresponding to 3 mg iron per
day from a dietary iron intake of 9 mg/day, i.e. considerably
less than the daily iron requirements during pregnancy. In the
average Scandinavian diet, the bioavailability of iron is
∼18%. Estimates from the USA suggest that the recom-
mended dietary allowance of iron should be ∼27 mg/day
with a bioavailability of at least 25% in order to fulfil the
needs during pregnancy (http://www.ific.org). However, in
order to obtain an iron intake of this magnitude, the
women should make unrealistic changes in their diet. As
we realise that dietary iron cannot fulfil iron require-
ments during pregnancy in the majority of women, the
Nordic Nutrition Recommendations have refrained from
giving recommendations for dietary iron intake [47].
Instead, they advocate oral iron supplements to women
with iron stores of <500 mg (corresponding to plasma
ferritin of <70 μg/L).
Oral iron prophylaxis
Placebo-controlled studies have consistently shown that
pregnant women using iron supplements [11, 30, 33–
41] have significantly higher iron status compared to
women taking placebo. Consequently, women taking
iron have a lower frequency of anaemia than women
taking placebo as shown in Tables 1 and 2. These
observations provide strong evidence that many pregnant
women not taking iron supplements have iron-deficient
erythropoiesis.
Previously, high doses of ferrous iron in the range 100–
200 mg/day were advocated to pregnant women [33, 34,
36, 40, 48]. A dose of 100 mg ferrous iron per day induces
a maximum rise in haemoglobin [33] and 200 mg ferrous
iron per day increases both plasma ferritin and haemoglobin
at delivery to the same levels as in non-pregnant women
[33, 48]. However, novel research have emphasised the
potential deleterious effects of iron on the human body [30]
and therefore encouraged studies using smaller doses of
iron [11, 35, 37] and studies trying to define the smallest
effective dose [12, 38, 41, 49].
European studies have shown that a supplement of 45–
66 mg ferrous iron per day taken between meals from 12 to
20 weeks gestation to delivery is adequate to prevent IDA
in healthy pregnant women [11, 35, 37, 39]. Even smaller
doses of 20–27 mg ferrous iron per day appear to have a
favourable influence on iron status [12, 30, 38, 41]. In a
Danish dose–response study [12], 40 mg ferrous iron per
day taken between meals was adequate to prevent IDA, but
20 mg iron per day was significantly inferior to 40 mg/day
as regards the prevention of iron deficiency. There was no
benefit in giving higher doses of iron, i.e. 60 or 80 mg. The
overall conclusion of these studies are firstly that 30–40 mg
ferrous iron per day appears adequate to prevent IDA and
secondly that low-dose iron supplements in the range 20–
27 mg/day are better than no supplements at all.
It would be convenient for the woman if iron supple-
ments could be taken as combined multivitamin–mineral
preparations. Nutritional supplements in Denmark designed
for pregnant women contain 15–27 mg ferrous iron.
However, a daily dose of 18 mg ferrous iron contained in
a multivitamin–mineral tablet taken from 16 weeks gesta-
tion is inadequate to prevent iron deficiency in 72% of the
women [49]. This is consistent with the fact that, in
epidemiological studies, daily use of multivitamin–mineral
tablets containing 14–18 mg ferrous iron has no impact on
iron status in women [50].
To the author’s knowledge, the absorption of iron
from multivitamin–mineral supplements has not been
evaluated. Probably, there is a low absorption of iron
for several reasons. Firstly, it is recommended that
multivitamin–mineral tablets should be taken with meals,
which clearly will reduce the bioavailability of iron.
Dietary components, e.g. calcium, polyphenols and
phytates, inhibit the absorption of ferrous iron supple-
ments ∼40%, especially at low doses of iron [51, 52].
Therefore, iron supplements should be taken between
meals, e.g. at bedtime, in order to ensure maximum
absorption [12]. Secondly, iron in multivitamin–mineral
supplements is administered together with other essential
divalent metal ions (zinc, copper, manganese, etc.), which
compete with each other about the absorptive capacity in
the gastrointestinal tract [30, 53, 54]. The consequence of
these considerations should be to withdraw iron from
multivitamin–mineral tablets designed for pregnancy and
administer iron in separate tablets.
As a consequence of these considerations, as general
iron prophylaxis to pregnant women, we recommend low-
dose ferrous iron supplement of 30–40 mg/day at bedtime
or between meals from early pregnancy or from the first
antenatal care visit to delivery [30, 44].
Due to the potential drawbacks of iron supplements,
individual iron prophylaxis based on assessment of iron
status (plasma ferritin) either prior to or in early preg-
nancy appears to be a more physiological approach than
general iron prophylaxis. Our recommendations for
individual iron prophylaxis have been stated previously
[30]. Women with plasma ferritin of >70 μg/L do not need
iron supplements; those with ferritin of 30–70 μg/L should
take 30–40 mg ferrous iron per day and those with ferritin
of <30 μg/L should take 80–100 mg ferrous iron per day
[30].
In conclusion, oral iron supplementation, general or
individual, in pregnant women starting in early preg-
nancy appears to very efficient in the prevention of
anaemia.
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Treatment of prepartum iron deficiency anaemia
IDA should be treated by replenishing body iron deficits
either by oral or intravenous administration of iron. In this
context, intramuscular administration of iron is hardly
applicable in the Western societies due to the small iron
dose per injection and the painful local reactions. Two
recent guidelines on prepartum anaemia have been
launched in 2007, by the Schweizerische Gesellschaft für
Gynäkologie und Geburtshilfe [55] and by the Network for
Advancement of Transfusion Alternatives (Table 3) [56].
Oral iron
Iron absorption is regulated according to body iron reserves
and the intensity of erythropoiesis. It is well documented that
exhausted body iron reserves in otherwise healthy women
will increase the intestinal iron absorption [52]. Furthermore,
the increased erythropoietin-induced erythropoiesis during
the second and third trimester [57] stimulates iron absorp-
tion. This combined stimulation of iron absorption has been
confirmed in studies showing that iron absorption increases
with increasing length of gestation, being most pronounced
after 20 weeks gestation [33, 58, 59]. However, the marked
increase in iron absorption is caused by iron deficiency, i.e.
pregnant women with replete iron stores have an absorp-
tion, which is almost similar to the absorption in non-
pregnant iron-replete women [33, 60].
This high iron absorption capacity is quite favourable for
treatment of IDA with oral iron in pregnant women. During
treatment of IDA, absorption is highest in the first 2 weeks
and subsequently declines [61]. There is consensus that oral
iron therapy should be the first therapeutic option in the
first and second trimester [55, 56]. Women having slight to
moderate IDA with haemoglobin of 90–105 g/L should
initially be treated with ferrous iron. The recommended
doses are traditionally quite high, i.e. 100–200 mg
elemental iron per day, being based on old studies
performed in anaemic men [61]. High-dose iron therapy
should preferably be administered as sustained release iron
preparations in order to optimise absorption and reduce
gastrointestinal side effects [62]. However, a recent study of
anaemic pregnant women has questioned the use of high-
dose oral iron therapy and presented evidence for the
efficiency of ferrous iron in doses of 20–80 mg/day, taken
between meals [63]. The effect on iron status increased with
iron dose (20→ 40→ 80 mg/day) and was highest with the
80-mg dose [63]. As a consequence of this study, the
recommended standard dose for treatment of IDA should
hardly exceed 100 mg ferrous iron per day taken between
meals. Following oral iron treatment for 2 weeks, the
therapeutic response should be checked by assessment of
haemoglobin. If haemoglobin has increased ≥10 g/L, oral
iron therapy should continue during the remaining period of
gestation with subsequent check of haemoglobin and
plasma ferritin. When haemoglobin has reached a level of
>105 g/L, the iron dose may be reduced to 60–80 mg/day
as maintenance therapy.
A failing haemoglobin response to treatment could be
the consequence of non-compliance due to psychological
mechanisms, non-compliance due to gastrointestinal side
effects, impaired gastrointestinal iron absorption due to
achlorhydria or inflammatory bowel disease or non-
recognised ongoing bleeding with iron losses.
Intravenous iron
Treatment with intravenous iron is clearly superior to oral
iron with respect to a faster increase in haemoglobin and faster
replenishment of body iron stores [64–66]. Intravenous iron
reduces the need for blood transfusions and constitutes an
alternative to transfusion in profound IDA [67]. Intravenous
iron preparations comprise among others iron sucrose
(Venofer®, Vifor, St. Gallen, Switzerland) [68], low molec-
ular weight iron dextran (Cosmofer®, Pharmacosmos,
Holbæk, Denmark) [69] and the recently introduced iron
carboxymaltose (Ferinject®, Vifor, St. Gallen, Switzerland)
[70]. Provided the Summary of Product Characteristics
(SPC) are observed, the frequency of adverse events is
below 0.5% [64, 65, 68–70]. Infusion of iron should be
Table 3 Guidelines for treatment of prepartum iron deficiency anaemia
Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe [55] Network for Advancement of Transfusion Alternatives [56]
Slight to moderate IDA=haemoglobin 90–105 g/L 1. Give oral iron in 1st and 2nd trimester
1. Give oral iron 160–200 mg/day
2. If haemoglobin increases to <10 g/L in 2 weeks (non-responders),
consider intravenous iron in second and third trimester
2. If haemoglobin increases <5 g/L in 2 weeks (non-responders),
consider intravenous iron at >14 weeks gestation
Severe IDA=haemoglobin<90 g/L
1. Give intravenous iron in separate doses of 200 mg until haemoglobin
is >105 g/L
3. Give intravenous iron in 3rd trimester
2. Consider maintenance therapy with oral iron
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given on an outpatient basis in a setting where equipment for
cardiopulmonary resuscitation is available. Infusion should
be given in peripheral veins and care should be taken to
avoid chemical phlebitis at the infusion site. In severe IDA
being resistant to oral iron, intravenous iron treatment can be
combined with the administration of recombinant human
erythropoietin of ∼20,000 U subcutaneously in order to
further stimulate the erythropoiesis [71].
Intravenous iron is considered safe in the second and
third trimester [55, 56]. There is limited experience in the
fist trimester concerning the potential teratogenic and/or
toxic effects on the foetus. Consequently, if parenteral iron
treatment is mandatory in the first trimester, the choice
stands between intravenous iron and blood transfusions, the
latter method carrying the well-known risks.
Treatment with intravenous iron should be considered at:
(1) as second option if oral iron fails to increase haemoglobin
within 2 weeks; (2) as first option at profound IDA, i.e.
haemoglobin of <90 g/L in any trimester beyond 14 weeks
gestation; (3) as first option at IDA in the third trimester.
Profound IDA has serious consequences for both the
pregnant women and the foetus [4–8] and requires prompt
intervention. In the first trimester, a combination of high-
dose oral and low-dose intravenous iron could be the choice,
otherwise blood transfusion should be considered. In the
second and third trimester, intravenous iron should be the
preferred treatment [56]. In the third trimester, there is too
short time for oral iron therapy to be effective and it is
imperative to alleviate IDA and replenish iron reserves prior
to delivery in order to prevent peripartum anaemia and avoid
blood transfusions. This is especially important in women
who for religious or other reasons oppose blood transfusions.
The dose of intravenous iron should be adequate to obtain
a haemoglobin level of >105 g/L. In the majority of women,
a total dose of 600–1,200 mg intravenous iron is adequate.
When a haemoglobin of >105 g/L has been reached, the
women can subsequently switch to maintenance treatment
with oral ferrous iron of 80–100 mg/day taken between
meals, provided they have normal gastrointestinal iron
absorption.
Iron sucrose should be given in repetitive doses of
maximum of 200 mg iron pro dosis dissolved in minimum
100 ml isotonic saline and infused over at least 30 min [55,
68]. Separate doses should be administered with ∼3-day
interval. Low molecular weight iron dextran is less prone to
produce hypotension (<0.1%) [69] than iron sucrose (<1%)
[68], while the frequency of serious adverse events appears
to be the same.
In non-pregnant patients, iron dextran can be administered
as “total dose infusion” where up to 20 mg iron per kilogram
body weight is given in a single infusion [69, 72]. However,
there is limited experience concerning its use in pregnancy.
According to the SPC [69], prior to the first administration, a
test dose of 25 mg iron dissolved in 100 mL isotonic saline
should be infused over 15 min. If no adverse reaction has
occurred 60 min after the test, 500–1,000 mg iron should be
dissolved in 500 mL isotonic saline and infused over 4 h. At
subsequent infusions, 25 mg iron should be infused over 15
min and, if no adverse reactions are seen, the remainder of
the infusion can be administered.
Iron carboxymaltose has recently been introduced on the
European market and has proved effective in the treatment of
postpartum anaemia [73]. According to the SPC [70], up to
1,000 mg iron dissolved in 250 mL isotonic saline can be
given as a single infusion over 15 min. However, due to the
limited experience with this novel iron compound, its use in
pregnant women should await further controlled clinical trials.
The total dose infusion concept, which is convenient for
the patient and save resources in the health care system, can
probably also be applied to pregnant women beyond the
first trimester, but the experience is until now scarce and
further controlled studies are needed. Intravenous iron
treatment appears effective in correcting both the anaemia
and quality-of-life deficits and shows promising aspects in
the future management of prepartum IDA.
Conclusion
Iron deficiency anaemia is the most frequent form of
anaemia in pregnant women. The diagnosis of IDA relies
on blood haemoglobin and plasma ferritin. Among fertile,
non-pregnant women, ∼40% have an unfavourable iron
status with respect to upcoming pregnancy. The prevalence
of prepartum anaemia in the third trimester ranges 14–52%
in women taking placebo and 0–25% in women taking iron
supplements. The frequency of IDA in placebo-treated
women ranges 12–17% and in iron-supplemented women
0–3%. Dietary measures are inadequate to reduce the
frequency of prepartum IDA, which, however, is prevented
by oral iron supplements 30–40 mg ferrous iron per day
taken at bedtime or between meals from early pregnancy to
delivery. Treatment of IDA should aim at replenishing body
iron deficits by oral and/or intravenous administration of
iron. In women with slight to moderate IDA treatment with
oral ferrous iron of ∼100 mg/day between meals is the
initial therapeutic option in the first and second trimester.
Treatment with intravenous iron is superior to oral iron
concerning the haematological response and is considered
safe in the second and third trimester.
Intravenous iron should be considered if oral iron fails to
increase haemoglobin within 2 weeks, at profound IDA
with haemoglobin of <90 g/L in any trimester beyond 14
weeks gestation and at IDA in the third trimester. Severe
IDA requires prompt intervention, especially in women
who for various reasons oppose blood transfusions.
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